Abstracts tagged "Biomarkers"

Abstract Number: 0605 • ACR Convergence 2024
Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Dennis McGonagle¹, Raja Atreya², Maria Abreu³, James Krueger⁴, Kilian Eyerich⁵, Robert Bissonnette⁶, Carrie Greving⁷, He Li⁸, Tom C. Freeman⁹, Amy Hart⁸, Brice Keyes⁷, Brian Stoveken⁸, John Hartman⁸, Kristin Leppard⁸, Jenna Parrett¹⁰, Joshua Wertheimer⁸, Indra Sarabia⁷, Janise Deming⁷, Kristen Kohler⁷, Christopher Ritchlin¹¹, Iain McInnes¹², Matthieu Allez¹³, Anne Fourie⁷ and Kacey Sachen⁷, ¹National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ²Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Leonard M. Miller School of Medicine, University of Miami, Miami, FL, ⁴The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, ⁵Karolinska Institute, Department of Medicine – Division of Dermatology and Venereology, Stockholm, Sweden; Medical Center, University of Freiburg, Freiburg, Germany, ⁶Innovaderm Research Inc., Montréal, QC, Canada, ⁷Janssen Research & Development, LLC, Immunology, San Diego, CA, ⁸Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹³Hôpital Saint-Louis, Université Paris Cité, Paris, France
Background/Purpose: IL-23 is implicated in the pathogenesis of psoriasis (PsO), and myeloid cells that express FcγRI (CD64) have been identified as a primary source of…
Abstract Number: 0710 • ACR Convergence 2024
High S100A4 Levels Associate with Inflammation and Vasculopathy in Systemic Sclerosis
Adela-Cristina Sarbu¹, Håvard Fretheim², Ladislav Šenolt³, Henriette Didriksen⁴, Cosimo Bruni⁵, Marco Sprecher⁶, Thor Ueland⁷, Jonas Hallén⁸, Rizwan Hussain⁹, Jörg Klingelhöfer¹⁰, Michal Tomcik¹¹, Yannick Allanore¹², Oliver Distler¹³ and Anna-Maria Hoffmann-Vold², ¹University Hospital Zurich, University of Zurich, Department of Rheumatology, Bern, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Oslo University Hospital, Moss, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitätsspital Zürich (University Hospital Zurich), Zürich, Switzerland, ⁷Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, ⁸Arxx Therapeutics, Oslo, Norway, Oslo, Norway, ⁹Agiana Therapeutics, Oslo, Norway, Oslo, Norway, ¹⁰Calluna Pharma, Oslo, Norway, Oslo, Norway, ¹¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ¹²Université Paris Cité, Paris, France, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: S100A4, a member of the S100 protein family, is implicated in various cellular processes. In systemic sclerosis (SSc), S100A4 is believed to contribute to…
Abstract Number: 0852 • ACR Convergence 2024
3-dimensional Shape Changes of the Knee over 4 Years Are Linear and Progressive but Much More Rapid in Osteoarthritic Joints: Data from the Osteoarthritis Initiative
Alan Brett¹, Philip G Conaghan² and Michael Bowes³, ¹Imorphics, Austin, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Imorphics, Manchester, United Kingdom
Background/Purpose: The specific bony changes of osteophyte growth and “bone attrition” (broadening and flattening of the femoral condyles) associated with OA have been recognized in…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1326 • ACR Convergence 2024
Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?
Laurence Duquenne¹, Didem Sahin Eroglu², Jianhua Wu³, Kate Harnden¹, Andrea Di Matteo⁴, Lucy Elizabeth Thornton⁵, Rahaymin Chowdhury⁵, Leticia Garcia-Montoya¹, Kulveer Mankia⁶ and Paul Emery⁶, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ²1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Ankara, Turkey, ³1. University of Leeds, Leeds Institute for Data Analytics, Leeds, United Kingdom 2.Wolfson Institute of Population Health/Queen Mary University of London, UK, Leeds, ⁴1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Jesi, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: A risk stratification model proposed a simple score using 4 biomarkers to identify those at high risk of developing inflammatory arthritis (IA) in primary…
Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Chen-Yu Lee¹, Matthew Caleb Marlin², Xiaoping Yang¹, Alessandra Ida Celia³, Vasileios Morkotinis⁴, Richard Furie⁵, Jill Buyon⁶, Chaim Putterman⁷, Jennifer Barnas⁸, Kenneth Kalunian⁹, Peter Izmirly¹⁰, Betty Diamond¹¹, Anne Davidson¹², Diane Kamen¹³, Jeff Hodgin¹⁴, the Accelerating Medicines Partnership RA/SLE¹⁵, Judith James², Michelle Petri¹⁶, Joel Guthridge², Avi Rosenberg¹ and Andrea Fava¹, ¹Johns Hopkins UNiversity, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Sapienza University of Rome, Rome, Italy, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Northwell Health, Manhasset, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Safed, Israel, ⁸University of Rochester, Rochester, NY, ⁹University of California San Diego, La Jolla, CA, ¹⁰New York University Grossman School of Medicine, New York, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Michigan, Michigan, ¹⁵multiple, multiple, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
Abstract Number: 2104 • ACR Convergence 2024
The Relationship of Soluble Biomarkers to OA Pain: A Systematic Literature Review
Sylvain Mathieu¹, Liisa Kuhi², Philip G Conaghan³, Niels Eijkelkamp⁴, Yves Henrotin⁵, Eva Kosek⁶, Hans-George Schaible⁷, Ali Mobasheri⁸, Kalle Kisand⁹ and Jérémie Sellam¹⁰, and GO-PAIN working group, ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²East Tallinn Central Hospital, Tallinn, Estonia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴University Medical Center, Umtrecht, Netherlands, ⁵MusculoSkeletal Innovative research Lab (mSKIL), Liege, Belgium, ⁶Karolinska Institute, Stockholm, Sweden, ⁷Institute of Physiology, Jena, Germany, ⁸Research Unit of Medical Imaging, Physics and Technology, Ouli, Finland, ⁹University of Tartu, Tartu, Estonia, ¹⁰Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Chronic joint pain is a major factor driving poor quality of life in people with osteoarthritis (OA). A better understanding of the complex mechanisms…
Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Philip Mease¹, Christopher Ritchlin², Lu Gao³, Peter Schafer⁴, Miroslawa Nowak³, Ian M. Catlett³ and Jinqi Liu³, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, BELLE MEAD, NJ
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
David Stevens¹, Lene Sundbakk², Amirhossein Kazemi², Marte Heiberg³, Tuulikki Sokka-Isler⁴, Bjorn Gudbjornsson⁵, Kristina Lend⁶, Anna Rudin⁷, Michael Nurmohamed⁸, Jon Lampa⁹, Merete Hetland¹⁰, Mikkel Ostergaard¹¹, Ronald Van Vollenhoven¹², Tillmann Uhlig², Espen Haavardsholm² and Hilde Hammer³, ¹St. Olavs hospital, Trondheim, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁴University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁷Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁹Karolinska University Hospital, Hässelby, Sweden, ¹⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
Abstract Number: 0608 • ACR Convergence 2024
Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Chau-Ching Liu⁵, Nicole Wilson⁵, Susan Manzi⁵ and Tyler O'Malley⁶, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Exagen, Vista, CA
Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
Abstract Number: 0713 • ACR Convergence 2024
Anti-muscarinic 3 Antibodies in SSc Associate with a More Significant GI and Extraintestinal Clinical Phenotype
Naveen Kalavar¹, Michael Hughes², Walter Morales³, Ami Shah⁴, Elizabeth Volkmann⁵, Roshan Dongre⁶, Mark Pimentel⁷, Laura Hummers⁸ and Zsuzsanna McMahan⁹, ¹University of Texas Health Science Center, Houston, TX, ²University of Manchester, Manchester, United Kingdom, ³Cedars-Sinai, Los Angeles, CA, ⁴Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, ⁶Methodist Hospital, Houston, TX, ⁷Cedars-Sinai, Los Angeles, ⁸Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁹UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease that negatively impacts internal organ function, including the gastrointestinal tract. While the etiology of…
Abstract Number: 0862 • ACR Convergence 2024
Two-year’s Worsening of Semi-quantitative MRI Features as Surrogate Outcomes for Long-term Incident Radiographic Knee Osteoarthritis After ACL-rupture
Jos Runhaar¹, Belle van Meer², Vernon Smit¹, mauro minnaard¹, Edwin Oei¹, Max Reijman¹ and Duncan Meuffels¹, ¹Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²St. Antonius Hospital Utrecht, Department of Sports Medicine, Utrecht, Netherlands
Background/Purpose: With an annual incidence rate of 2-5% in high-risk populations, the use of established knee OA as an outcome challenges the feasibility of preventive…

« Previous Page
1
…
6
7
8
9
10
…
96
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].